Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | CALML3 | P27482 | 1/20 | 0.39 |
| ▸ | SDHA | P31040 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748931 | 0.84 | PDE3B (0.41) | PDE3BPDE3AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL30748750 | 0.84 | MTOR (0.36) | RAD51MTORMAOBLMNAMAOA | |
| SCHEMBL30749097 | 0.80 | MAPT (0.44) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL30749139 | 0.76 | MAOB (0.41) | MAOBLMNAMAOAPTGS1CALML3 | |
| SCHEMBL30748801 | 0.72 | ELANE (0.37) | ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL30749100 | 0.72 | PRKDC (0.42) | RAD51ALDH1A1SMN1; SMN2 | |
| SCHEMBL30749140 | 0.71 | MAPT (0.39) | RAD51LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL30749007 | 0.71 | ELANE (0.44) | ALDH1A1 | |
| SCHEMBL30748903 | 0.68 | ALOX15 (0.35) | — | |
| SCHEMBL30748982 | 0.68 | PGR (0.37) | RAD51ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | RAD51 2049/4885MTOR 1201/4885MAOB 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.